Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in Advanced/Recurrent Ovarian Cancer
ChiCTR-OIC-17010304Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Jan 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in ovarian cancer and cervical squamous cell carcinoma (CSCC), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: progression free survival. Started Jan 2017; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
ovarian cancercervical squamous cell carcinoma (CSCC)
Beyond the preview
Go deeper on ChiCTR-OIC-17010304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-17010304.